Panobinostat and donor lymphocyte infusions in patients with high-risk AML and MDS

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Gesine Bug, MD from University Hospital Frankfurt, Frankfurt/Main, Germany discusses a clinical trial with 40 high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients treated with panobinostat and donor lymphocyte infusions (DLI). Promising results of the study showing that the combination of the two treatments has a potential to inhibit a disease relapse will be validated further in a randomised clinical trial next year.

Share this video